Methylation testing: what to look for beyond MTHFR

Patients walk into practitioner offices with a direct-to-consumer test result in their hand and a single phrase on their mind: “I’m MTHFR positive.” That’s a starting point. It’s not a workup.

A real methylation assessment looks at three layers: the genetics that describe your pathway, the functional markers that describe whether the pathway is currently working, and the clinical picture that tells you whether any of this matters for you. If you only look at one layer, you miss the other two.

Here’s what a complete methylation workup actually includes — and why most “MTHFR tests” are asking 10% of the question.

Layer 1: Genetics beyond MTHFR

MTHFR gets the attention because it has the clearest enzyme-activity reduction (30–70% depending on variant and copy number) and it’s the most-studied gene in the pathway. But the methylation cycle is a chain — and a chain can break at any link. These are the genes practitioners usually want to see together.

MTHFR (C677T, A1298C)

The entry point. C677T reduces conversion of folate and folic acid into 5-MTHF. A1298C has a milder effect but can compound with C677T in compound heterozygotes. We covered this in depth in what is MTHFR.

MTR and MTRR

MTR (methionine synthase) catalyzes the hand-off of the methyl group from folate to B12 to homocysteine. MTRR (methionine synthase reductase) keeps the B12 cofactor in its active state. The MTRR A66G variant is associated with modest elevations in homocysteine, independent of folate and B12 intake — roughly a 4% increase in cardiovascular risk in some populations [1]. Patients with MTR or MTRR variants often need more aggressive B12 support than MTHFR-only carriers.

COMT (Val158Met)

Catechol-O-methyltransferase clears dopamine, norepinephrine, and estrogen metabolites by methylating them. The Val158Met polymorphism changes how fast this happens, and dopaminergic-drug response varies meaningfully by COMT genotype [2]. Met/Met carriers clear dopamine more slowly; Val/Val carriers clear it faster. In clinical practice, some Met/Met patients report lower tolerance of aggressive methyl-donor loading and may feel irritable or restless on high-dose 5-MTHF, so practitioners often titrate carefully based on genotype. COMT genotype changes both the dosing and the feel of methylation support.

BHMT

BHMT handles the alternate route: re-methylating homocysteine using betaine (from choline/TMG) instead of folate + B12. Variants in BHMT can shift which pathway your body leans on. Patients with heavy MTHFR + MTR burden sometimes respond particularly well to TMG or choline support because BHMT is their working backup.

CBS

Cystathionine β-synthase is the entry point into the trans-sulfuration pathway — where homocysteine gets cleared into glutathione instead of recycled into methionine. CBS variants influence how much sulfur-containing substrate ends up downstream. This is the branch that produces your antioxidant defense.

MAO-A

Not strictly a methylation gene, but it lives in the same neurotransmitter-metabolism neighborhood. Monoamine oxidase A breaks down serotonin, dopamine, and norepinephrine. MAO-A variants interact with COMT to determine neurotransmitter turnover rates — useful context when mood and focus symptoms are prominent.

A practitioner-grade nutrigenomic panel like GenePro+ reports all of these plus a hundred more across 11 wellness categories. A consumer MTHFR-only test reports two SNPs and calls it a day.

Layer 2: Functional markers (the blood tests)

Genetics tell you what your pathway might do. Functional markers tell you what it’s actually doing right now. A practitioner wants to see both.

Homocysteine

The single most useful functional readout of methylation. Elevated homocysteine (typically >10 µmol/L, though labs vary) means the cycle isn’t efficiently re-methylating back to methionine — some combination of low folate, low B12, low B2, low B6, or genetic bottleneck. Homocysteine normalizing after bioactive B-vitamin support is how you confirm the protocol is working [3].

Serum B12 vs. holotranscobalamin vs. methylmalonic acid

This is where a lot of B12 workups go wrong. Serum B12 measures all forms of the vitamin in circulation — but only about 20% of that is biologically available (the part bound to transcobalamin). Patients can have “normal” serum B12 and functional deficiency.

Holotranscobalamin (holoTC) measures just the active B12. Methylmalonic acid (MMA) rises when cellular B12 is insufficient. In a large diagnostic-accuracy study of over 11,000 samples, holoTC outperformed serum B12 for detecting subclinical deficiency (AUC 0.92 vs 0.90), with MMA close behind (0.91) [4]. If your B12 workup is just a single serum B12, you may be missing real deficiency.

Red blood cell folate

Plasma folate reflects recent dietary intake; RBC folate reflects longer-term tissue status (roughly the preceding 3–4 months). Patients on folic acid may have normal plasma folate but still carry unmetabolized folic acid (UMFA) in circulation because their MTHFR can’t process it. UMFA is detectable in >95% of US serum samples, and about 30% of adults have levels exceeding 1 nmol/L [5]. High UMFA alongside low RBC folate is a classic “folic acid is being supplied but not activated” pattern.

B6 (pyridoxal-5-phosphate)

Functional B6 status. Low P5P impairs the trans-sulfuration branch, where homocysteine becomes glutathione.

Hormone and organic acid markers (advanced)

For patients with complex presentations, an organic acids test (OAT) can catch functional B-vitamin insufficiencies that blood work misses — methylmalonic acid, FIGlu (forminoglutamate, which rises with functional folate deficiency), and xanthurenate (which rises with functional B6 deficiency). These aren’t first-line tests but they matter for complicated cases.

Q: Can I just skip the bloodwork and go straight to genetics?

A: No, and this is the most common mistake we see. Genetics describe capacity; bloodwork describes reality. A person with a C677T homozygous MTHFR variant but a homocysteine of 7 µmol/L and normal RBC folate is doing fine and doesn’t need heroic dosing. A person with wild-type MTHFR but a homocysteine of 14, low holoTC, and high UMFA has a real problem — just not a genetic one. Treat what’s actually broken, not what might theoretically be.

Layer 3: Symptoms and clinical picture

Neither genetics nor bloodwork means much if they don’t map to how you feel. The clinical picture that should raise methylation suspicion:

• Persistent fatigue not relieved by sleep
• Brain fog, slow recall, poor stress tolerance
• Anxiety, low mood, irritability
• Sensitivity to medications, alcohol, or caffeine (effects feel stronger or last longer than in others)
• Frequent migraines
• History of recurrent miscarriage, elevated homocysteine, or cardiovascular events in close relatives
• Poor response to SSRIs or other mood medications

A patient with three of these plus high homocysteine is a much higher-priority methylation case than one with just a gene-test flag and no symptoms. For the symptom-to-chemistry mapping in more detail, see how methylation shapes mood, focus, and energy.

Putting the three layers together

The practitioner workflow we see most often:

1. Symptom screen — Is there clinical reason to suspect methylation?
2. Baseline labs — Homocysteine, holoTC or serum B12 + MMA, RBC folate, and ideally P5P
3. Nutrigenomic panel — MTHFR, MTR, MTRR, COMT, BHMT, CBS, MAO-A, and related genes
4. Interpret together — What does the genetics suggest as capacity? What do the labs show is actually happening? What does the patient report?
5. Protocol — Targeted cofactor support, start low, retest homocysteine in 8–12 weeks

This is how you avoid the two most common errors: over-treating asymptomatic gene carriers and under-treating symptomatic non-carriers.

The short version

• “MTHFR testing” by itself is a screening tool, not a workup.
• A complete methylation genetic panel includes MTHFR, MTR, MTRR, COMT, BHMT, CBS, and MAO-A at minimum.
• Functional markers — homocysteine, holotranscobalamin, MMA, RBC folate, P5P — describe whether the pathway is actually working, which genetics alone can’t tell you.
• Symptoms close the loop: genetics and labs don’t matter if they don’t map to a clinical picture worth treating.

If you want the full-pathway view in one test — 100+ markers across 11 wellness categories, including every major methylation gene plus downstream nutrient-processing SNPs — GenePro+ is designed for exactly this. If you already have test results and know your profile, Methylation Complete™ is the daily bioactive B-vitamin base most protocols build from.

---

This article is educational and does not constitute medical advice. Genetic and laboratory testing should be interpreted by a qualified healthcare provider. Supplementation protocols are individualized.

References

1. Gaughan DJ, Kluijtmans LAJ, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001;157(2):451–456. PMID: 11472746
2. Schacht JP. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. Pharmacogenomics J. 2016;16(5):430–438. PMID: 27241058
3. Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228–232. PMID: 10896698
4. Jarquin Campos A, Risch L, Nydegger U, et al. Diagnostic Accuracy of Holotranscobalamin, Vitamin B12, Methylmalonic Acid, and Homocysteine in Detecting B12 Deficiency in a Large, Mixed Patient Population. Dis Markers. 2020;2020:7468506. PMID: 32089757
5. Pfeiffer CM, Sternberg MR, Fazili Z, et al. Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults. J Nutr. 2015;145(3):520–531. PMID: 25733468